影像学中的新型放射性药物工具
本综述总结了核医学显像探针在生理参数(如代谢)和化合物性质(如亲脂性、化学稳定性)方面的限制,并讨论了克服这些限制的已有方法和新方向。文中还提出了一种基于脂质纳米颗粒的「特洛伊木马」式放射性配体递送新概念,该概念尚待探索。
要点
- 核医学显像的优势在于放射性探针化合物,但受代谢等生理参数及亲脂性、化学稳定性等化合物性质限制。
- 许多有前景的化合物因上述限制未能用于核医学显像。
- 脂质纳米颗粒作为载体系统的「特洛伊木马」递送策略在核医学中尚待探索。
核心结论
- 本综述概述了显像探针的可能限制以及克服这些限制的方法或技术,并提出了脂质纳米颗粒作为核医学载体系统的尚待探索概念。
研究设计与样本
- 本文为综述,聚焦于中枢活性化合物的显像,但许多问题在靶向外周器官时同样出现。
主要发现
- 核医学显像的优势在于用作放射性探针的化合物,但存在与代谢等生理参数以及亲脂性、化学稳定性等化合物性质相关的诸多限制。
- 由于这些限制,许多原本有前景的化合物未能用于核医学显像。
- 除已有的克服限制的方法外,文中讨论了一些迄今尚未探索的新方向。
- 文中提出了一种「特洛伊木马」式放射性配体运输新工具,脂质纳米颗粒可能作为核医学载体系统。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The strength of Nuclear Medicine imaging are the compounds to be used as radioactive probes. Unfortunately there are many constraints both in relation to physiological parameters such as metabolism as well to compound related properties like lipophilicity or chemical stability. Due these constraints, many, otherwise promising, compounds could not be used in Nuclear Medicine imaging. Within this review a brief summary is given regarding possible limitations for imaging probes and approaches or techniques to overcome the constraints. Even so the review focuses on imaging with central active compounds, many of these problems appear likewise when targeting peripheral organs. Besides the established approaches to overcome limitations some new, so far not explored, directions are discussed. Finally, a potential new tool in imaging will be presented, a trojan horse approach for transportation of radioligands. Here, like in conventional drug development, lipid nanoparticles may have potential to be used as carrier systems in Nuclear Medicine as well. This, so far not explored, concept is briefly presented.
引用
- Bender D. New Radiopharmaceutical Tools in Imaging. Semin Nucl Med. 2025. PMID: 40425427. doi:10.1053/j.semnuclmed.2025.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。